A practical reference on Nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Physical activity can be related to a person's professional activities, non-work related daily activities like walking or cycling, or it can be in the form of activities such as recreation or team sports. The specific type of activity can be tailored to populations such as children, pregnant women, and elderly adults. Tailored activity to one's fitness level also encourages the body to heal properly and prevent any injuries as a result of exercise. Physical inactivity leads to less energy expenditure and is a factor that impacts obesity rates in both children and adults. Physical inactivity has become a worldwide concern since inactivity also elevates the risk of heart disease. With a regular active lifestyle it can reduce the risk for noncommunicable diseases like diabetes, heart disease, and dyslipidemia (high cholesterol). Physical activity not only reduces the risk of noncommunicable diseases, but it also can benefit the body such as improving sleep patterns, reducing both anxiety and depression, and of course, helps weight loss and weight management.
=== Anion exchange === Anion exchange sorbents are derivatized with positively charged functional groups that interact and retain negatively charged anions, such as acids. Strong anion exchange sorbents contain quaternary ammonium groups that have a permanent positive charge in aqueous solutions, and weak anion exchange sorbents use amine groups which are charged when the pH is below about 9. Strong anion exchange sorbents are useful because any strongly acidic impurities in the sample will bind to the sorbent and usually will not be eluted with the analyte of interest; to recover a strong acid a weak anion exchange cartridge should be used. To elute the analyte from either the strong or weak sorbent, the stationary phase is washed with a solvent that neutralizes the charge of either the analyte, the stationary phase, or both. Once the charge is neutralized, the electrostatic interaction between the analyte and the stationary phase no longer exists and the analyte will elute from the cartridge.
In 1879, Walther Hesse (1846-1911) and Friedrich Hugo Härting published the study "Lung Cancer, the Miners' Disease in the Schneeberg Mines". Hesse, a pathologist, was shocked by the poor health and young age of the miners. This particular form of bronchial carcinoma was given the name Schneeberg disease because it occurred among miners in the Schneeberg mines (Saxon Erz Mountains). When Hesse's report was published, radioactive radiation and the existence of radon were unknown. It was not until 1898 that Marie Curie-Skłodowska (1867-1934) and her husband Pierre Curie (1859-1906) discovered radium and created the concept of radioactivity. Beginning in the fall of 1898, Marie Curie suffered from inflammation of the fingertips, the first known symptoms of radiation sickness. In the Jáchymov mines, where silver and non-ferrous metals were mined from the 16th to the 19th century, uranium ore was mined in abundance in the 20th century. It was only during the Second World War that restrictions were imposed on ore mining in the Schneeberg and Jáchymov mines. After World War II, uranium mining was accelerated for the Soviet atomic bomb project and the emerging Soviet nuclear industry. Forced labor was used. Initially, these were German prisoners of war and displaced persons, and after the February Revolution of 1948, political prisoners were imprisoned by the Communist Party regime in Czechoslovakia, as well as conscripted civilian workers. Several "Czechoslovak gulags" were established in the area to house these workers.
Sources: en.wikipedia.org
18 October — The Primary Principals Collective Bargaining Union accepts a 2.5% pay rise offer following four months of negotiations with the Ministry of Education. This will be followed by another 2.1% pay rise in 2026. 20 October: The New Zealand Government introduces two new requirements for job seeker beneficiaries who have failed a welfare obligation: engaging in three job search activities weekly and attending at least one employment-training course per month. A measles case linked to international travel is reported in Auckland. 21 October: Strong winds cause power outages, fallen trees and disrupt road and rail travel across the Wairarapa region. Lines company Powerco reports that 10,000 houses in the area have lost electricity due to fallen power lines. Strong winds and heavy rains disrupt road, rail and air travel in the Wellington Region. One person is killed by a fallen tree branch in Mount Victoria during a storm that hits Wellington. Strong winds cause four vegetation fires in the Hawke's Bay Pōrangahau area, leading to the evacuation of vie homes. Strong winds and dry conditions cause six fires in the Kaikōura District, leading to the destruction of 14 buildings and local evacuations. Three new measles cases are reported in Manawatū and Nelson. 22 October: Fire and Emergency New Zealand deploys numerous firefighters and helicopters to combat fires in the Kaikōura District and Pōrangahau. Strong winds and fires cause power outages and flight disruptions through the lower North Island and upper South Island.
== General principles == In a common FPLC strategy, a resin is chosen that the protein of interest will bind to by a charge interaction while in buffer A (the running buffer) but become dissociated and return to solution in buffer B (the elution buffer). A mixture containing one or more proteins of interest is dissolved in 100% buffer A and pumped into the column. The proteins of interest bind to the resin while other components are carried out in the buffer. The total flow rate of the buffer is kept constant; however, the proportion of buffer B (the "elution" buffer) is gradually increased from 0% to 100% according to a programmed change in concentration (the "gradient"). At some point during this process each of the bound proteins dissociates and appears in the eluant. The eluant passes through two detectors which measure salt concentration (by conductivity) and protein concentration (by absorption of ultraviolet light at a wavelength of 280 nm). As each protein is eluted, it appears in the eluant as a "peak" in protein concentration, and can be collected for further use.
Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease (EC 3.4.21.68) found on endothelial cells lining the blood vessels. Human tPA is encoded by the PLAT gene, and has a molecular weight of ~70 kDa in the single-chain form. tPA can be manufactured using recombinant biotechnology techniques, producing types of recombinant tissue plasminogen activator (rtPA) such as alteplase, reteplase, and tenecteplase. These drugs are used in clinical medicine to treat embolic or thrombotic stroke, but they are contraindicated and dangerous in cases of hemorrhagic stroke and head trauma. The antidote for tPA in case of toxicity is aminocaproic acid.
=== International Actors' Involvement === The international community played a significant role in brokering and overseeing the Algiers Peace Accords. Algeria, as the lead mediator, had considerable influence due to its geographical proximity and historical engagement in Mali's conflicts. The mediation process also involved various international entities, including the United Nations, France, the African Union, the European Union, ECOWAS, and the United States. Despite this broad international support, the mediation faced criticism for failing to adequately address core issues at the heart of the conflict. For example, Algeria’s role as a mediator was often seen as controversial due to its long-standing political and military influence in northern Mali. Additionally, many accused Algeria of partiality, given the close ties between the Coordination of Azawad Movements (CMA) and Algerian officials. Some CMA leaders even held dual citizenship. International actors, such as the United Nations and France, also came under scrutiny for prioritising counterterrorism operations, notably through France’s Operation Barkhane, rather than focusing on the political aspects of the accord. This imbalance caused friction between the peace process and efforts to combat jihadist groups in the region.
Sources: en.wikipedia.org
== Murders and assaults == While she was a nurse at Caressant Care, Wettlaufer began injecting some of the patients she cared for with insulin. In some cases, the amount was not enough to kill the patient; she was charged with, and confessed to, aggravated assault or attempted murder for those cases. Wettlaufer's first assaults occurred sometime between June 25 and December 31, 2007. She confessed that she injected sisters Clotilde Adriano (age 87) and Albina Demedeiros (88) with insulin. While they later died, their deaths were not attributed to Wettlaufer. She confessed to two counts of aggravated assault. The first case in which Wettlaufer injected a patient with enough insulin to directly cause death was on August 11, 2007, when she murdered James Silcox (84), a World War II veteran and father of six. From 2007 to March 2014, Wettlaufer also murdered the following patients at Caressant Care:
In the spring of 1778, a heavy chain supported by huge log rafts was stretched across the Hudson from West Point to Constitution Island to impede the movement of British ships north of West Point. A second log boom (resembling a ladder in construction) spanned the river about 100 yards (90 m) downstream to absorb the impact of any ship attempting to breach the barrier. The Hudson River's changing tides, strong current, and frequently unfavorable winds created adverse sailing conditions at West Point. Compounding this, the river's narrow width and sharp "S-Curve" there forced any large ship to tack in order to navigate it. Cannon were placed in forts and artillery batteries on both sides of the river to attack ships when they were slowed to a halt by the Patriot barrier placed there. The chain was constructed over six weeks at the Sterling Iron Works in Warwick, Orange County. The multiple forge-fire site and trip hammer was rediscovered in 2008 within Sterling Forest State Park. When completed, the 600-yard (550 m) chain contained iron links two feet (0.6 m) in length, weighing 140 to 180 pounds (64 to 82 kg). The links were carted to New Windsor, where they were put together and floated down the river to West Point on logs late in April. Including swivels, clevises, and anchors, the chain weighed 65 tons. For buoyancy, logs were cut into 16-foot (5 m) lengths, waterproofed, and joined by fours into rafts fastened to one another with 12-foot (3.7 m) timbers.
==== Mechanical properties ==== DBHA exhibits shear thinning behaviour and at low strains, storage and loss moduli are independent of strain but past a critical strain, the hydrogel yields and is transformed from a solid to a liquid.
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
West of Borgo Dora stands Rione Valdocco ('Valdocco neighbourhood'), enclosed by Via Cigna, Corso Regina Margherita, Corso Principe Oddone and the River Dora. This neighbourhood hosts the significant architecture of Santuario di Maria Ausiliatrice ('Maria Ausiliatrice Sanctuary') in the homonymous square and behind the church stands San Pietro in Vincoli old cemetery. Overall, the main thoroughfares of the West side of Aurora are Via Cigna, which crosses the district from north to south, Corso Vercelli, a historical avenue starting north of the River Dora, and Corso Principe Oddone, part of the long Spina Centrale boulevard that will be built over the underground Turin-Milan railway. However, the Spina Centrale project is proceeding slowly because of the lack of funds and the boulevard is still occupied by a large worksite along its span. Once completed, Aurora district will be connected to Eastern San Donato, thanks to a better connection among the roads of the two adjacent districts (i.e. Corso Ciriè will continue in Corso Gamba and Strada del Fortino in Corso Rosai). As for the rest of Aurora, the district is crossed by an important thoroughfare named Corso Giulio Cesare, a long boulevard that extends from Porta Palazzo up to Turin-Trieste motorway entrance in the northern urban fringe of Turin. Other significant roads are Corso Palermo, Via Bologna and Corso Regio Parco, mostly in the East side of Aurora which is known as Borgo Rossini ('Rossini Borough').
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.